PLRX’s beta can be found in Trading Information at the top of this page. A stock’s beta measures how closely tied its price movements have been to the performance of the overall market. Upgrade to MarketBeat All Access to add more stocks to your watchlist.
Do the numbers hold clues to what lies ahead for the stock? Pliant Therapeutics, Inc. (PLRX) delivered earnings and revenue surprises of -1.52% and 31.87%, respectively, for the quarter ended March 2023. Style is an investment factor that has a meaningful impact on investment risk and returns.
This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.32% per year. These returns cover a period from January 1, 1988 through July 31, 2023. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return.
According to the issued ratings of 11 analysts in the last year, the consensus rating for Pliant Therapeutics stock is Buy based on the current 11 buy ratings for PLRX. The average twelve-month price prediction for Pliant Therapeutics is $48.36 with a high price target of $63.00 and a low price target of $33.00. Currently, the analyst consensus on Arcus Biosciences is a Strong Buy with an average price target of $42.13, which is an 89.9% upside from current levels. In a report issued on August 23, Truist Financial also reiterated a Buy rating on the stock with a $50.00 price target.
Pliant Therapeutics stock indicated to open at $25, or 56% above $16 IPO price
The company was founded by Bradley Backes, Bill De Grado, Hal Chapman, and Dean Sheppard in June 2015 and is headquartered in South San Francisco, CA. Pliant Therapeutics Inc. upsized its planned initial public offering on Tuesday, saying in a regulatory filing that it plans to offer 9 million shares, up from an earlier 6 million. TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities. One share of PLRX stock can currently be purchased for approximately $16.45.
According to TipRanks.com, Pohlman is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -29.1% and a 20.0% success rate. Pohlman covers the Healthcare sector, focusing on stocks such as Sonnet BioTherapeutics Holdings, Mersana Therapeutics, and Gritstone Oncology. According to TipRanks.com, Lebovitz is a 3-star analyst with an average return of 1.6% and a 53.5% success rate. Lebovitz covers the Healthcare sector, focusing on stocks such as BioMarin Pharmaceutical, Ionis Pharmaceuticals, and Mirum Pharmaceuticals. High-growth stocks tend to represent the technology, healthcare, and communications sectors.
Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2022 Financial Results
Sign-up to receive the latest news and ratings for PLRX and its competitors with MarketBeat’s FREE daily newsletter. The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 14th 2023. Pliant Therapeutics’ stock was trading at $19.33 at the beginning of the year. Since then, PLRX stock has decreased by 14.9% and is now trading at $16.45. Sign-up to receive the latest news and ratings for Pliant Therapeutics and its competitors with MarketBeat’s FREE daily newsletter.
Citigroup, Cowen and Piper Sandler acted as the underwriters for the IPO and Needham & Company was co-manager. PLRX, +2.62% soared about 75% in premarket trading on Monday, the day after the company said a high dose of its experimental treatment for idiopathic pulmonary fibro… Pliant Therapeutics, Inc. (PLRX) delivered earnings and revenue surprises of -2.86% and 27.10%, respectively, for the quarter ended December 2022.
MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation. The economic situation appears to be grim, with higher interest rates and the recent turmoil in the financial system causing sluggish growth in the first three months of this year. The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%. An industry with a larger percentage of Zacks Rank #1’s and #2’s will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4’s and #5’s. Plus, PLRX info will be updated daily in your Zacks.com Portfolio Tracker – also free.
- Data may be intentionally delayed pursuant to supplier requirements.
- Dividend yield allows investors, particularly those interested in dividend-paying stocks,
to compare the relationship between a stock’s price and how it rewards stockholders through dividends.
- Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month.
- The company’s experimental idiopathic pulmonary fibrosis drug is showing a lot of promise.
We’d like to share more about how we work and what drives our day-to-day business. Compare
PLRX’s historical performance
against its industry peers and the overall market.
NewsPliant Therapeutics Inc.PLRX
There’s also a VGM Score (‘V’ for Value, ‘G’ for Growth and ‘M’ for Momentum), which combines the weighted average of the individual style scores into one score. The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style. Pliant Therapeutics, Inc. engages in the discovery and development of therapies for fibrotic diseases. The company is pursuing drug development programs for a range of fibrotic diseases, focusing on tissue-specific integrin modulation and TGF-ß1 signaling inhibition.
Style is calculated by combining value and growth scores, which are first individually calculated. Data are provided ‘as is’ for informational purposes only and are not intended for trading purposes. Data may be intentionally delayed pursuant to supplier requirements. Pliant Therapeutics Inc. shares soared 55% in their trading debut https://1investing.in/ Wednesday, after the company’s initial public offering priced at $16 a share, the high end of its $14 to $16 range. These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies. The technique has proven to be very useful for finding positive surprises.
The Barchart Technical Opinion rating is a 100% Sell with a Average short term outlook on maintaining the current direction. Pliant Therapeutics zoomed 34% higher and added to that gain in the next session.This followed good news about clinical trials for a lung-condition treatment. The company’s experimental idiopathic pulmonary fibrosis drug is showing a lot of promise. The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank. Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.
Pliant Therapeutics’ stock is owned by many different retail and institutional investors. Insiders that own company stock include Bernard Coulie, Eric Lefebvre, Hans Hull, Keith Lamont Cummings, Matthew Dunnigan and Mike Ouimette. (PLRX) raised $90 million in an initial public offering on Wednesday, June 3rd 2020. The company issued 6,000,000 shares at a price of $14.00-$16.00 per share.
How we use your personal data
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Liquidia Technologies with a $12.50 average price target. According to TipRanks.com, Harrison is a 4-star analyst with an average return of 8.6% and a 39.6% success rate. Harrison covers the Healthcare sector, focusing on stocks such as MoonLake Immunotherapeutics, Rani Therapeutics Holdings, and Protagonist Therapeutics.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Analysts like Pliant Therapeutics more than other Medical companies. The consensus rating for Pliant Therapeutics is Buy while the average consensus rating for medical companies is Moderate Buy.
BTIG analyst Kaveri Pohlman maintained a Buy rating on Arcus Biosciences yesterday and set a price target of $70.00. BTIG analyst Julian Harrison reiterated a Buy rating on Liquidia Technologies yesterday and set a price target of $18.00. In a report released today, David Lebovitz from Citi maintained a Buy rating on Pliant Therapeutics, with a price target of $50.00. The company’s shares closed last Wednesday at $17.01, close to its 52-week low of $15.88. At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors.
The Barchart Technical Opinion widget shows you today’s overally Barchart Opinion with general information on how to interpret the short and longer term signals. Unique to Barchart.com, Opinions analyzes a stock or commodity using 13 popular analytics in short-, medium- and long-term periods. Results are interpreted as buy, sell or hold signals, each with numeric ratings and summarized with an overall percentage buy or sell rating. After each calculation the program assigns a Buy, Sell, or Hold value with the study, depending on where the price lies in reference to the common interpretation of the study. For example, a price above its moving average is generally considered an upward trend or a buy.
11 brokerages have issued 1 year price targets for Pliant Therapeutics’ stock. Their PLRX share price forecasts range from $33.00 to $63.00. On average, they expect the company’s share price to reach $48.36 in the next twelve months. This suggests a possible upside of 194.0% from the stock’s current price. View analysts price targets for PLRX or view top-rated stocks among Wall Street analysts.
Currently, the analyst consensus on Pliant Therapeutics is a Strong Buy with an average price target of $48.64, implying a 188.5% upside from current levels. Wainwright also maintained a Buy rating on the stock with a $50.00 price target. 11 Wall Street research analysts have issued “buy,” “hold,” and “sell” ratings for Pliant Therapeutics in the last year. The consensus among Wall Street research analysts is that investors should “buy” PLRX shares.
- High-growth stocks tend to represent the technology, healthcare, and communications sectors.
- The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Liquidia Technologies with a $12.50 average price target.
- Sign-up to receive the latest news and ratings for PLRX and its competitors with MarketBeat’s FREE daily newsletter.
- In a report released today, David Lebovitz from Citi maintained a Buy rating on Pliant Therapeutics, with a price target of $50.00.
- More value-oriented stocks tend to represent financial services, utilities, and energy stocks.
- Pliant Therapeutics’ stock was trading at $19.33 at the beginning of the year.
Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have central limit theorem in machine learning been excluded from these return calculations. Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. According to analysts, Pliant Therapeutics’s stock has a predicted upside of 128.87% based on their 12-month price targets.
They rarely distribute dividends to shareholders, opting for reinvestment in their businesses. More value-oriented stocks tend to represent financial services, utilities, and energy stocks. These are established companies that reliably pay dividends. PLRX does not currently have a forward dividend yield. Dividend yield allows investors, particularly those interested in dividend-paying stocks,
to compare the relationship between a stock’s price and how it rewards stockholders through dividends.
Shares of Pliant Therapeutics (PLRX) have been rising since management reported positive interim data from a mid-stage study evaluating a higher dose of its lead pipeline candidate in IPF patients. Zacks Earnings ESP (Expected Surprise Prediction) looks to find companies that have recently seen positive earnings estimate revision activity. The idea is that more recent information is, generally speaking, more accurate and can be a better predictor of the future, which can give investors an advantage in earnings season. As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style. The scores are based on the trading styles of Value, Growth, and Momentum.